Balancing How Much We Want to Know with What We Are Willing to Pay: A Comparative Cost Analysis of Prenatal Cytogenetic Testing and Screening Strategies
Preferred prenatal strategies vary among stakeholders. However, as monopolies (large systems and Accountable Care Organizations) now control the majority of American healthcare policy decisions, the lowest cost cfDNA screening will likely prevail in actual practice.
Authors
- Mark I. Evans (ORCID: https://orcid.org/0000-0002-1705-799X)
- Lawrence Prensky (ORCID: https://orcid.org/0000-0003-4427-9122)
- Howard Cuckle (ORCID: https://orcid.org/0000-0003-2450-2403)
Institutions
- Tel Aviv University (IL)
- National University of Singapore (SG)
- Mount Sinai Hospital (US)
- BVI (United States) (US)
- Fetal Medicine Foundation of America (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Fetal Diagnosis and Therapy
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1159/000549331
- Citations
- 1
- Primary Topic
- Prenatal Screening and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.49